RhumbLine Advisers’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $193M | Sell |
3,347,347
-300,221
| -8% | -$17.2M | 0.15% | 103 |
|
|
2026
Q1 | $221M | Buy |
3,647,568
+67,577
| +2% | +$3.94M | 0.19% | 83 |
|
|
2025
Q4 | $193M | Sell |
3,579,991
-84,776
| -2% | -$4.08M | 0.16% | 103 |
|
|
2025
Q3 | $165M | Sell |
3,664,767
-128,722
| -3% | -$6.01M | 0.13% | 123 |
|
|
2025
Q2 | $176M | Buy |
3,793,489
+246,546
| +7% | +$12.1M | 0.15% | 110 |
|
|
2025
Q1 | $216M | Sell |
3,546,943
-107,291
| -3% | -$6.25M | 0.2% | 85 |
|
|
2024
Q4 | $207M | Sell |
3,654,234
-31,175
| -0.8% | -$1.74M | 0.18% | 86 |
|
|
2024
Q3 | $191M | Sell |
3,685,409
-134,772
| -4% | -$6.32M | 0.17% | 101 |
|
|
2024
Q2 | $159M | Buy |
3,820,181
+46,882
| +1% | +$2.1M | 0.15% | 115 |
|
|
2024
Q1 | $205M | Buy |
3,773,299
+1,609
| +0% | +$82K | 0.2% | 92 |
|
|
2023
Q4 | $194M | Sell |
3,771,690
-172,245
| -4% | -$9.04M | 0.2% | 92 |
|
|
2023
Q3 | $229M | Sell |
3,943,935
-30,510
| -0.8% | -$1.87M | 0.27% | 62 |
|
|
2023
Q2 | $254M | Buy |
3,974,445
+53,481
| +1% | +$3.59M | 0.28% | 56 |
|
|
2023
Q1 | $272M | Buy |
3,920,964
+47,826
| +1% | +$3.37M | 0.34% | 48 |
|
|
2022
Q4 | $279M | Buy |
3,873,138
+165,927
| +4% | +$12.5M | 0.37% | 43 |
|
|
2022
Q3 | $264M | Buy |
3,707,211
+95,154
| +3% | +$6.9M | 0.39% | 40 |
|
|
2022
Q2 | $278M | Buy |
3,612,057
+88,790
| +3% | +$6.76M | 0.41% | 40 |
|
|
2022
Q1 | $257M | Sell |
3,523,267
-35,397
| -1% | -$2.38M | 0.33% | 49 |
|
|
2021
Q4 | $222M | Buy |
3,558,664
+48,746
| +1% | +$2.86M | 0.27% | 65 |
|
|
2021
Q3 | $208M | Sell |
3,509,918
-139,632
| -4% | -$9.2M | 0.28% | 63 |
|
|
2021
Q2 | $244M | Sell |
3,649,550
-223,034
| -6% | -$14.5M | 0.32% | 54 |
|
|
2021
Q1 | $244M | Sell |
3,872,584
-151,460
| -4% | -$9.42M | 0.33% | 56 |
|
|
2020
Q4 | $250M | Sell |
4,024,044
-22,305
| -0.6% | -$1.37M | 0.34% | 53 |
|
|
2020
Q3 | $244M | Sell |
4,046,349
-9,513
| -0.2% | -$573K | 0.38% | 51 |
|
|
2020
Q2 | $238M | Buy |
4,055,862
+87,029
| +2% | +$5.21M | 0.4% | 43 |
|
|
2020
Q1 | $221M | Buy |
3,968,833
+8,325
| +0.2% | +$509K | 0.46% | 36 |
|
|
2019
Q4 | $254M | Buy |
3,960,508
+1,186,702
| +43% | +$68M | 0.43% | 37 |
|
|
2019
Q3 | $141M | Buy |
2,773,806
+62,074
| +2% | +$2.92M | 0.26% | 72 |
|
|
2019
Q2 | $123M | Buy |
2,711,732
+19,136
| +0.7% | +$891K | 0.23% | 80 |
|
|
2019
Q1 | $128M | Buy |
2,692,596
+50,323
| +2% | +$2.51M | 0.25% | 75 |
|
|
2018
Q4 | $137M | Buy |
2,642,273
+9,171
| +0.3% | +$493K | 0.3% | 61 |
|
|
2018
Q3 | $163M | Sell |
2,633,102
-41,621
| -2% | -$2.47M | 0.32% | 59 |
|
|
2018
Q2 | $148M | Buy |
2,674,723
+19,533
| +0.7% | +$1.05M | 0.3% | 63 |
|
|
2018
Q1 | $168M | Sell |
2,655,190
-31,381
| -1% | -$2.02M | 0.35% | 52 |
|
|
2017
Q4 | $165M | Buy |
2,686,571
+68,390
| +3% | +$4.28M | 0.33% | 53 |
|
|
2017
Q3 | $167M | Buy |
2,618,181
+20,935
| +0.8% | +$1.22M | 0.36% | 48 |
|
|
2017
Q2 | $145M | Buy |
2,597,246
+47,600
| +2% | +$2.59M | 0.33% | 54 |
|
|
2017
Q1 | $139M | Buy |
2,549,646
+33,766
| +1% | +$1.85M | 0.32% | 55 |
|
|
2016
Q4 | $147M | Buy |
2,515,880
+68,332
| +3% | +$3.74M | 0.37% | 46 |
|
|
2016
Q3 | $132M | Buy |
2,447,548
+98,484
| +4% | +$6.33M | 0.36% | 47 |
|
|
2016
Q2 | $173M | Buy |
2,349,064
+89,086
| +4% | +$6.29M | 0.51% | 39 |
|
|
2016
Q1 | $144M | Buy |
2,259,978
+73,387
| +3% | +$4.63M | 0.45% | 41 |
|
|
2015
Q4 | $150M | Sell |
2,186,591
-14,078
| -0.6% | -$930K | 0.48% | 37 |
|
|
2015
Q3 | $130M | Buy |
2,200,669
+26,953
| +1% | +$1.71M | 0.44% | 40 |
|
|
2015
Q2 | $145M | Sell |
2,173,716
-327,639
| -13% | -$21.6M | 0.46% | 39 |
|
|
2015
Q1 | $161M | Buy |
2,501,355
+2,046
| +0.1% | +$128K | 0.47% | 45 |
|
|
2014
Q4 | $148M | Sell |
2,499,309
-41,024
| -2% | -$2.31M | 0.43% | 42 |
|
|
2014
Q3 | $130M | Sell |
2,540,333
-14,884
| -0.6% | -$743K | 0.39% | 48 |
|
|
2014
Q2 | $124M | Sell |
2,555,217
-137,022
| -5% | -$6.75M | 0.36% | 53 |
|
|
2014
Q1 | $140M | Sell |
2,692,239
-34,250
| -1% | -$1.82M | 0.41% | 47 |
|
|
2013
Q4 | $145M | Sell |
2,726,489
-114,873
| -4% | -$5.85M | 0.43% | 46 |
|
|
2013
Q3 | $131M | Sell |
2,841,362
-44,849
| -2% | -$1.97M | 0.41% | 45 |
|
|
2013
Q2 | $129M | Buy |
+2,886,211
| New | +$125M | 0.41% | 45 |
|
Other funds holding BMY
RhumbLine Advisers's BMY Position: Q2 2026 in Review
RhumbLine Advisers reduced its Bristol-Myers Squibb (BMY) stake by 8.2% in Q2 2026, selling an estimated $17.2M and leaving 3,347,347 shares worth $193M. The position accounts for 0.15% of the portfolio, ranked #103.
RhumbLine Advisers first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $279M in Q4 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- RhumbLine Advisers held 3,347,347 shares of Bristol-Myers Squibb worth $193M as of Q2 2026.
- RhumbLine Advisers sold 300,221 Bristol-Myers Squibb shares in Q2 2026, an estimated $17.2M.
- Bristol-Myers Squibb made up 0.15% of RhumbLine Advisers's portfolio in Q2 2026, its #103 holding.
- RhumbLine Advisers first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Bristol-Myers Squibb position peaked at $279M in Q4 2022.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.